Vinorelbine (Oral) Plus Trastuzumab for 1st-line Treatment of HER2/Neu Overexpressing Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Carcinoma Breast Stage IV
Interventions: DRUG: Navelbine|DRUG: Herceptin|DRUG: Navelbine (oraly)
Sponsor: Ludwig-Maximilians - University of Munich
Collaborators: Pierre Fabre Laboratories